The Patent Finder
CT

Cymabay Therapeutics, Inc.

First filing 2002
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Metabolex, Inc. (to 2013)

28 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
15 more records may belong here and await a decision; they are not counted.

The next term ends in Dec 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
5
Ending by 2030
Dec 2027
Next term end
9
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Treatment of NAFLD and NASH US 9,381,181
The most cited patent in this portfolio, cited by 155 later US patents, top 5% of utility patents granted in 2016 in our data. Protection runs to 2035.
Ends Apr 2035 · High confidence
Also notable
5-Ethyl-2-{4-[4-(4-Tetrazol-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE US 7,638,541
Cited by 64 later US patents, top 25% of utility patents granted in 2009 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Ends Dec 2027 · High confidence
Also notable
Treatment of Intrahepatic Cholestatic Diseases US 9,486,428
The largest patent family in this portfolio, 10 related applications, renewed at every maintenance window due so far. Protection runs to 2035.
Ends Mar 2035 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 9, 2027
    The maintenance fee for Treatment of NAFLD and NASH (US 10,342,770) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
  • 1 fee due Apr 6, 2027
    The maintenance fee for Substituted TETRAZOL-1-YL-PHENOXYMETHYL-THIAZOL-2-YL-PIPERIDINYL-PYRIMIDINE Salts (US 9,150,567) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
  • 1 fee due May 19, 2027
    The maintenance fee for Treatment of intrahepatic cholestatic diseases (US 10,478,411) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
  • 1 fee due Jun 24, 2027
    The maintenance fee for Treatment of intrahepatic cholestatic diseases (US 10,512,622) comes due Jun 24, 2027. Unpaid by Dec 27, 2027, it lapses early.
  • 1 fee due Jul 26, 2027
    The maintenance fee for Compositions of 5-Ethyl-2-{4-[4-(4-Tetrazol-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE (US 9,241,924) comes due Jul 26, 2027. Unpaid by Jan 26, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 terms have ended since Aug 21, 2026

What they patent

The largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,638,5415-Ethyl-2-{4-[4-(4-Tetrazol-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE
In force
 · High confidence
In forceHigh confidence
US 8,921,350Heterocyclic Receptor Agonists for the Treatment of Diabetes and Metabolic Disorders
In force
 · Medium confidence
In forceMedium confidence
US 8,975,258Heterocyclic Receptor Agonists for the Treatment of Diabetes and Metabolic Disorders
In force
 · Medium confidence
In forceMedium confidence
US 11,007,162Methods of Reducing Small, Dense LDL Particles
In force
 · High confidence
In forceHigh confidence
US 9,150,567Substituted TETRAZOL-1-YL-PHENOXYMETHYL-THIAZOL-2-YL-PIPERIDINYL-PYRIMIDINE Salts
In force
 · High confidence
In forceHigh confidence
US 9,241,924Compositions of 5-Ethyl-2-{4-[4-(4-Tetrazol-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE
In force
 · High confidence
In forceHigh confidence
US 8,703,776Agonists of GPR131 and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,593,109Bicyclic Agonists of GPR131 and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,486,428Treatment of Intrahepatic Cholestatic Diseases
In force
 · High confidence
In forceHigh confidence
US 9,808,436Treatment of Intrahepatic Cholestatic Diseases
In force
 · High confidence
In forceHigh confidence
10 of 28 patents shown.
Pro members see all 28.
Pro members: see all 28 patents
Also on record, not counted in the 28: 51 patents ended · 8 applications pending · 24 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited